fluorouracil - Profile

What are the generic sources for fluorouracil and what is the scope of patent protection?

Fluorouracil is the generic ingredient in seven branded drugs marketed by Extrovis, Chartwell Rx, Accord Hlthcare, Dr Reddys Labs Sa, Encube, Taro, Hill Dermaceuticals, Pharmacia And Upjohn, Teva Parenteral, Abic, Abraxis Pharm, Alembic, Bedford, Ebewe Pharma, Eugia Pharma Speclts, Fresenius Kabi Usa, Gland, Kindos, Marchar, Novast Labs, Sagent Pharms Inc, Sandoz, Smith And Nephew, Spectrum Pharms, Teva Pharms Usa, Avyxa Holdings, and Elorac, and is included in fifty NDAs. Additional information is available in the individual branded drug profile pages.

There are two tentative approvals for this compound.

Summary for fluorouracil

US Patents:	0
Tradenames:	7
Applicants:	27
NDAs:	50

Generic filers with tentative approvals for FLUOROURACIL

Applicant	Application No.	Strength	Dosage Form
		1GM/20ML (50MG/ML)	INJECTABLE;INJECTION
		500MG/10ML (50MG/ML)	INJECTABLE;INJECTION
		5GM/100ML (50MG/ML)	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FLUOROURACIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CARAC	Cream	fluorouracil	0.5%	020985	1	2011-07-29

US Patents and Regulatory Information for fluorouracil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Extrovis	CARAC	fluorouracil	CREAM;TOPICAL	020985-001	Oct 27, 2000		RX	Yes	Yes
Extrovis	EFUDEX	fluorouracil	CREAM;TOPICAL	016831-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Chartwell Rx	FLUOROPLEX	fluorouracil	CREAM;TOPICAL	016988-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Accord Hlthcare	FLUOROURACIL	fluorouracil	CREAM;TOPICAL	214845-001	Oct 7, 2021	AB	RX	No	No
Dr Reddys Labs Sa	FLUOROURACIL	fluorouracil	CREAM;TOPICAL	077524-001	Apr 11, 2008	AB	RX	No	No
Encube	FLUOROURACIL	fluorouracil	CREAM;TOPICAL	216942-001	Feb 12, 2025	AB	RX	No	No
Extrovis	FLUOROURACIL	fluorouracil	CREAM;TOPICAL	203122-001	Apr 20, 2015		DISCN	No	No

Expired US Patents for fluorouracil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hill Dermaceuticals	TOLAK	fluorouracil	CREAM;TOPICAL	022259-001	Sep 18, 2015
Extrovis	CARAC	fluorouracil	CREAM;TOPICAL	020985-001	Oct 27, 2000
Extrovis	CARAC	fluorouracil	CREAM;TOPICAL	020985-001	Oct 27, 2000

Investment Scenario and Fundamentals Analysis for Fluorouracil

Last updated: February 20, 2026

What is Fluorouracil and Why Is It Significant?

Fluorouracil (5-FU) is a pyrimidine analog used as an antimetabolite in chemotherapy. Approved since the 1960s, it remains a core treatment for colorectal, breast, head and neck, and gastric cancers. Despite its age, fluorouracil retains a role in combination regimens and in biosimilar markets owing to its established efficacy and low manufacturing costs.

Market Overview and Trends

Parameter	Value / Trend	Source
Global oncology drug market	US$171 billion in 2022, CAGR 7.5% projected until 2028	[1]
Fluorouracil market size	Estimated US$0.8 billion in 2022; modest growth	[2]
Key production regions	China, India, Europe	[3]
Biosimilar presence	Increasing, particularly in Europe and emerging markets	[4]

The oncology segment continues expanding due to aging populations, rising cancer incidence, and improved diagnosis. Fluorouracil's longstanding presence generates stable demand, especially in combination therapies for advanced cancers.

Product and Regulatory Status

• Formulations: Intravenous injections, topical formulations (for actinic keratosis), and compounded products.
• Regulatory approvals: Approved by FDA, EMA, and other authorities; biosimilar versions exist.
• Patent landscape: No active patents for original formulations; biosimilars face patent expiry around 2015-2020 in key markets, fostering generic competition.

Fundamental Forces Influencing Investment

Efficacy and Clinical Use

Fluorouracil remains a mainstay in combination chemotherapy regimens. Its effectiveness across multiple cancer types supports ongoing demand, though newer agents like capecitabine (oral prodrug) challenge its dominance.

Manufacturing and Supply Chain

Manufacturing is well-established, with key players in China and India providing cost advantages. Patent expiries have allowed multiple biosimilar manufacturers to enter the market, exerting price pressures but stabilizing supply.

Market Competition

Key competitors include capecitabine, tegafur-based regimens, and emerging targeted therapies. Biosimilars have driven prices down in developed markets, elevating volume-based sales.

Regulatory Environment

Stringent regulatory standards demand consistent quality. Recent policies favor biosimilar approvals, accelerating market penetration but increasing competitive pressure.

Innovation and Future Outlook

Research explores delivery optimizations, such as nanoparticle formulations, and combination strategies to improve efficacy and reduce toxicity. However, pipeline innovations are primarily incremental.

Financial Considerations

Metric	Data	Comments
Revenue stability	Consistent in existing markets; limited growth expected	Due to entrenched clinical role
Pricing dynamics	Declining in mature markets due to biosimilars	Pressure from generics/biosimilars
R&D pipeline	Minimal; primarily focused on formulation improvements	Few novel compounds in development
Investment risk	Moderate; influenced by patent expiry, biosimilar competition	Sector stable but mature

SWOT Analysis

Strengths	Weaknesses
Established efficacy	Generics and biosimilars limit pricing power
Wide acceptance in clinical guidelines	Vulnerable to market saturation and newer agents

Opportunities	Threats
Biosimilar expansion into emerging markets	Patent expiry in mature markets erodes revenue
Formulation innovations	Competition from targeted therapies

Key Investment Considerations

• The core product faces mechanical pressures from biosimilars and generics, leading to margin erosion.
• Market growth in developing regions offers expansion opportunities.
• Clinical adoption remains high, limiting downside unless replaced by superior therapies.
• Production costs are low, maintaining profitability even at lower prices.

Conclusion

Fluorouracil presents an investment with steady cash flows driven by global clinical reliance and biosimilar proliferation. Risks include market saturation, evolving treatment standards, and pricing pressures. Diversification into formulation innovations could mitigate some challenges but remains limited by industry maturity.

Key Takeaways

• Fluorouracil retains core role in chemotherapy, but its market growth prospects are moderate.
• Biosimilar competition and patent expiries have lowered margins in mature markets.
• Emerging markets and formulation advancements provide growth avenues.
• Innovation pipeline remains limited; focus shifts to cost management and biosimilar strategies.
• Investors should consider the drug's stability against near-term patent erosion and competitive pressures.

FAQs

1. How does biosimilar competition impact fluorouracil’s market?
Biosimilars in developed markets have driven prices down, reducing profit margins but increasing volume sales in emerging markets where biosimilar penetration is lower.

2. What are the main therapeutic alternatives to fluorouracil?
Capecitabine, tegafur-based agents, and targeted therapies like monoclonal antibodies in combination regimens are substitutes with oral delivery advantages or improved tolerability.

3. What is the outlook for fluorouracil’s patent protection?
Original patents expired mainly around 2015-2020 in key territories, resulting in increased biosimilar market entry and competitive pressure.

4. Are there ongoing innovations that could revive fluorouracil sales?
Formulation innovations such as nanoparticle delivery and combination strategies are under research but have yet to translate into significant revenue boosts.

5. How sustainable is fluorouracil’s revenue base long-term?
It remains relatively stable due to established clinical utility, but revenue growth is constrained by patent expiries, biosimilar competition, and the advent of targeted therapies.

---

References

1. GlobalData. (2022). Oncology market report.
2. MarketResearch.com. (2022). Fluorouracil market analysis.
3. ICIS. (2021). Pharmaceutical raw material supply chains.
4. European Medicines Agency. (2021). Biosimilar guidelines.